Things Get Worse For Gilead’s Magrolimab
Company Pauses Solid Tumor Study Enrollment
Gilead said the FDA requested a partial clinical hold on the studies as well, just over a week after the drug maker said it would not develop the magrolimab further for blood cancers.
